coibamide a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

coibamide A: from the Panamanian marine cyanobacterium Leptolyngbya sp.; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	24881184
CHEMBL ID	3354442
MeSH ID	M0522969

Synonyms (4)

Synonym
CHEMBL3354442
coibamide a
DTXSID601018181
1029227-48-2

Research Excerpts

Overview

Coibamide A (CbA) is a marine natural product with potent antiproliferative activity against human cancer cells and a unique selectivity profile. It was isolated from a marine cyanobacterium as part of an International Cooperative Biodiversity Groups (ICBG) program.

Excerpt	Reference	Relevance
"Coibamide A is a highly potent antiproliferative cyclic depsipeptide, which was originally isolated from a Panamanian marine cyanobacterium. "	( Synthesis and biological evaluation of the [d-MeAla(11)]-epimer of coibamide A. Fujii, N; Hau, AM; Ishmael, JE; McPhail, KL; Misu, R; Nabika, R; Ohno, H; Oishi, S; Suyama, TL, 2015)	2.1
"Coibamide A (CbA) is a marine natural product with potent antiproliferative activity against human cancer cells and a unique selectivity profile. "	( Coibamide A Targets Sec61 to Prevent Biogenesis of Secretory and Membrane Proteins. Ishmael, JE; Kawaguchi, S; Kazemi, S; Kellosalo, J; Mattos, DR; McPhail, KL; Oishi, S; Paatero, AO; Paavilainen, VO; Richter, U; Serrill, JD; Thornburg, CC; Tranter, D; Vogel, WK; Wan, X, 2020)	3.44
"Coibamide A is a potent cancer cell toxin and one of a select group of natural products that inhibit protein entry into the secretory pathway via a direct inhibition of the Sec61 protein translocon. "	( Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin A. Badr, CE; Dolan, BP; Ishmael, JE; Kawaguchi, S; Kazemi, S; Mattos, DR; McPhail, KL; Moasser, MM; Oishi, S; Paavilainen, VO; Ruiz-Saenz, A; Serrill, JD, 2021)	2.29
"Coibamide A is a cytotoxic marine natural product that induces mTOR-independent autophagy as an adaptive stress response that precedes cell death."	( ATG5 Promotes Death Signaling in Response to the Cyclic Depsipeptides Coibamide A and Apratoxin A. Ganley, IG; Humphreys, IR; Ishmael, JE; McPhail, KL; Serrill, JD; Tan, M; Wan, X, 2018)	1.44
"Coibamide A is an N-methyl-stabilized depsipeptide that was isolated from a marine cyanobacterium as part of an International Cooperative Biodiversity Groups (ICBG) program based in Panama. "	( Coibamide A induces mTOR-independent autophagy and cell death in human glioblastoma cells. Ganley, IG; Greenwood, JA; Hau, AM; Ishmael, JE; Löhr, CV; McPhail, KL; Proteau, PJ; Serrill, JD, 2013)	3.28
"Coibamide A is a highly potent antiproliferative cyclodepsipeptide originally isolated from a Panamanian marine cyanobacterium. "	( Efficient Synthesis and Stereochemical Revision of Coibamide A. Fang, L; Pan, Z; Su, W; Wang, W; Wu, C; Yao, G, 2015)	2.11
"Coibamide A is a cytotoxic lariat depsipeptide isolated from a rare cyanobacterium found within the marine reserve of Coiba National Park, Panama. "	( Coibamide A, a natural lariat depsipeptide, inhibits VEGFA/VEGFR2 expression and suppresses tumor growth in glioblastoma xenografts. Alani, AW; Coleman, DJ; Hau, AM; Indra, AK; Ishmael, JE; Jang, HS; McPhail, KL; Serrill, JD; Wan, X, 2016)	3.32
"Coibamide A (1) is a new, potent antiproliferative depsipeptide which was isolated from a marine Leptolyngbya cyanobacterium collected from the Coiba National Park, Panama. "	( Coibamide A, a potent antiproliferative cyclic depsipeptide from the Panamanian marine cyanobacterium Leptolyngbya sp. Gerwick, WH; Goeger, DE; Hills, P; Huang, N; McPhail, KL; Medina, RA; Mooberry, SL; Ortega-Barría, E; Romero, LI, 2008)	3.23

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay ID	Title	Year	Journal	Article
AID1175714	Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2	Synthesis and biological evaluation of the [d-MeAla(11)]-epimer of coibamide A.
AID1387467	Growth inhibition of human PANC1 cells incubated for 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	Improved Total Synthesis and Biological Evaluation of Coibamide A Analogues.
AID1175715	Cytotoxicity against human SF295 cells assessed as growth inhibition after 72 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2	Synthesis and biological evaluation of the [d-MeAla(11)]-epimer of coibamide A.
AID1175712	Cytotoxicity against human NCI-H292 cells assessed as growth inhibition after 72 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2	Synthesis and biological evaluation of the [d-MeAla(11)]-epimer of coibamide A.
AID1387466	Growth inhibition of human A549 cells incubated for 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	Improved Total Synthesis and Biological Evaluation of Coibamide A Analogues.
AID1175713	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2	Synthesis and biological evaluation of the [d-MeAla(11)]-epimer of coibamide A.
AID1387465	Growth inhibition of human MDA-MB-231 cells incubated for 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	Improved Total Synthesis and Biological Evaluation of Coibamide A Analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (8.33)	29.6817
2010's	7 (58.33)	24.3611
2020's	4 (33.33)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	22.31 (24.57)
Research Supply Index	2.56 (2.92)
Research Growth Index	5.58 (4.65)
Search Engine Demand Index	18.60 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (22.31)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	12 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
thapsigargin Thapsigargin: A sesquiterpene lactone found in roots of THAPSIA. It inhibits SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES.. thapsigargin : An organic heterotricyclic compound that is a hexa-oxygenated 6,7-guaianolide isolated fron the roots of Thapsia garganica L., Apiaceae. A potent skin irritant, it is used in traditional medicine as a counter-irritant. Thapsigargin inhibits Ca(2+)-transporting ATPase mediated uptake of calcium ions into sarcoplasmic reticulum and is used in experimentation examining the impacts of increasing cytosolic calcium concentrations.	2.17	1	0	butyrate ester; organic heterotricyclic compound; sesquiterpene lactone	calcium channel blocker; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
apratoxin a apratoxin A: a potent cytotoxin with a novel skeleton, has been isolated from the marine cyanobacterium Lyngbya majuscula Harvey ex Gomont; structure in first source. apratoxin A : An aprotoxin having the common aprotoxin cyclodepsipeptide skeleton where the isoleucyl residue carries an N-methyl substituent and the side-chain adjacent to the lactone is tert-butyl.	2.88	3	0	1,3-thiazoles; apratoxin	antineoplastic agent; metabolite

Condition	Relationship Strength	Studies
Benign Neoplasms [description not available]	2.11	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.11	1
Breast Cancer [description not available]	2.88	3
Breast Neoplasms Tumors or cancer of the human BREAST.	2.88	3
Astrocytoma, Grade IV [description not available]	2.13	1
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	7.13	1
Cancer of Lung [description not available]	2.04	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.04	1

chemdatabank.com